Zopiclone
| Zopiclone | |
|---|---|
 | |
| Molecular structure via molpic based on CDK |
| Rotamer [] | |
|---|---|
| Conformer structure via 3Dmol.js |
| Physical properties [] | |
|---|---|
| Molecular mass | 388.8 g/mol [1] |
| Melting point | 178 °C [1] |
| Solubility | 8.85e-01 g/L [1] |
| Predicted LogP | 0.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C17H17ClN6O3 [1] |
| IUPAC name | [6-(5-chloro-2-pyridinyl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate [1] |
| SMILES | CN1CCN(CC1)C(=O)OC2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl [1] |
| InChI | InChI=1S/C17H17ClN6O3/c1-22-6-8-23(9-7-22)17(26)27-16-14-13(19-4-5-20-14)15(25)24(16)12-3-2-11(18)10-21-12/h2-5,10,16H,6-9H2,1H3 [1] |
| InChIKey | GBBSUAFBMRNDJC-UHFFFAOYSA-N [1] |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | ~5 hours (3.5 – 6.5 hours) ~7 – 9 hours for 65+ years old |
| Dosing[] |
|---|
| Sublingual [] | |
|---|---|
| Light | ≤ 6.8 mg(6x - 27.3%) |
| Common | 6.8 - 8.8 mg(5x - 22.7%) |
| Strong | 8.8 - 10 mg(7x - 31.8%) |
| Heavy | 10 - 14.7 mg(1x - 4.5%) |
| Extreme | 14.7 mg +(3x - 13.6%) |
| Oral [] | |
|---|---|
| Light | ≤ 13.2 mg(10x - 47.6%) |
| Common | 13.2 - 20 mg(5x - 23.8%) |
| Strong | 20 - 22.5 mg(1x - 4.8%) |
| Heavy | 22.5 - 30 mg(5x - 23.8%) |
| Extreme | 30 mg + |
Statistically derived dosages via DBI-IGS We do not take any responsibility for medical complications or loss of life sustained by following these dosages blindly. |
Zopiclone (also known as Imovane, Amoban, Zimovane, Zopiclona, Zopiclonum, Ximovan, RP-27267, [6-(5-chloropyridin-2-yl)-5-oxo-7H-pyrrolo[3,4-b]pyrazin-7-yl] 4-methylpiperazine-1-carboxylate, RP 27267 or Zimovane LS) is a
Chemistry
Stereochemistry []
Zopiclone is a racemic mixture of the enantiomers.
| Stereoisomerism |
|---|
| Stereoisomer enumberation with rdkit |
Druglikeness
Lipinski's rule of five
Zopiclone matches Lipinski's rule of five.Pharmacology
ATC Classification
In the nervous system (N) zopiclone acts as a benzodiazepine related drug (N05CF), hypnotics and sedative (N05C), psycholeptic (N05) and zopiclone (N05CF01).[1]Subjective effects []
| magnus / Zopiclone [] | |
|---|---|
Routes:
| |
Legal status []
- Australia: Zopiclone is a S4 substance.[2]
- Brazil: Zopiclone is a B1 substance.
- Canada: Zopiclone is a prescription only substance.
- United Kingdom: Zopiclone is a Class C5 -restricted substance.
- New Zealand: Zopiclone is a Class C substance.
- United States: Zopiclone is a Schedule I under the "Controlled Substances Act (CSA)".
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 5735, Zopiclone. Accessed June 12, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/5735
Therapeutic Goods (Poisons Standard— June 2025) Instrument 2025. May 1, 2025. Accessed June 12, 2026. https://www.legislation.gov.au/F2025L00599/asmade/2025-05-28/text/original/pdf